2017 Was Epic
The landscape around us looks much different today than it did just one year ago. As our industry changes within the evolving pharmaceutical ecosystem, we must speak with one voice to drive home the message that a robust generic drug and biosimilars marketplace is necessary to sustain affordable health care.Jeff Watson Chairman of the Board, AAM
President, Global Generics, Apotex Inc.
In 2017, against a challenging and new political backdrop, the generic and biosimilars industry forged ahead to support the reauthorization of the fundamental laws governing our work, crystalize our value proposition in the minds of policymakers and advocate for sustainable competition.
Increased awareness and understanding are the keys to realizing greater patient access to generics and biosimilars. The industry, through the association, took control of its narrative in 2017 and told the story of generics and biosimilars to critical stakeholder groups – from lawmakers in Washington to state legislators, from the media to patient and consumer organizations.
Together, [our] substantive actions have amplified our voice, enhanced our influence and enabled us to begin reclaiming the narrative that generic drugs drive savings.Chip Davis President and CEO, AAM
Read how 2017 was an epic year for AAM's storytelling and advocacy: